Journal article
In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
Abstract
SOURCE CITATION: Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10:888-99. 35617986.
Authors
Tran A; Rochwerg B
Journal
Annals of Internal Medicine, Vol. 175, No. 10,
Publisher
American College of Physicians
Publication Date
10 2022
DOI
10.7326/j22-0074
ISSN
1056-8751